Polyspecific Antibodies in Lymphoproliferative T-cell Disorders — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Polyspecific Antibodies in Lymphoproliferative T-cell Disorders — Stella

Recruiting

Back to Peripheral T Cells Lymphoma (PTCL) trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(8 sites)

France

CHU de Caen, Caen

CHU de Clermont-Ferrand, Clermont-Ferrand

CHU Henri-Mondor, Créteil

CHU de Bordeaux - GH Sud - Hôpital Haut-Lévêque, Pessac

CHU de Lyon - Hôpital Lyon Sud, Pierre-Bénite

Key details

Phase

First-in-human testing / Safety & dosing

Sponsor

Xenothera SAS

Enrollment target

~54 participants

Started

July 2024

Primary completion

July 2026

Age range

18 Years and older

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov